Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of ...

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on ...

Sarepta Therapeutics, Inc. stock fell after an ELEVIDYS-related death. However, click for why strong SRTP revenue growth and ...

Advanced Micro Devices (AMD) stock is on the rise after Piper Sandler analysts lifted their price target for the stock to $140. Sarepta Therapeutics (SRPT) stock plunges after the company reported a ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...